10 completed, 2 unknown, 1 terminated. 13 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 13 | Completed 10, Unknown 2, Terminated 1 |
Follow Pupil Disorders: new trials by email Literature Review of Pupil Disorders trials Research Report on Pupil Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of the MydCombi on Pupillary Dilation in Pediatric and Adult Patients MydCombi Device, MydCombi Drug - Dilation, Pupil Reaction Absent | Phase 4 | Completed | University of California, San Francisco | 70 | 2024-10-01 | 2026-09-22 |
| Safety and Efficacy of Fixed Combination Phenylephrine-Tropicamide for Pupil Dilation MydCombi - Mydriasis | Phase 4 | Completed | Eyenovia Inc. | 30 | 2023-11-28 | 2024-04-18 |
| Wearing-Off Period of Pharmacological Dilation and Anisocoria Tropicamide, 1% Pilocarpine, Proparacaine Hydrochloride - Anisocoria | Phase 4 | Completed | Prisma Health-Upstate | 11 | 2022-04-01 | 2023-03-07 |
| Efficacy and Safety of Mydriatic Microdrops for Retinopathy Of Prematurity Screening Microdrop administration of phenylephrine 1.67% and tropicamide 0.33%, Standard drop administration of phenylephrine 1.67% and tropicamide 0.33% - Retinopathy of Prematurity | Phase 4 | Completed | Aristotle University Of Thessaloniki | 83 | 2021-09-07 | 2025-03-18 |
| Evaluation of Pupil Dilation Speed With the MAP Dispenser tropicamide-phenylephrine fixed combination ophthalmic solution - Mydriasis | Phase 4 | Completed | Eyenovia Inc. | 61 | 2021-05-24 | 2025-01-09 |
| Efficacy and Safety of Mydriatic Microdrops Compared With Standard Drops for Retinopathy of Prematurity (ROP) Screening: a Pilot Randomized Clinical Trial Microdrop administration [phenylephrine 1.67% + tropicamide 0.33% (drop volume: 6-7 μL)], Standard drop administration [phenylephrine 1.67% + tropicamide 0.33% (drop volume: 28-34 μL)] - Retinopathy of Prematurity | Phase 4 | Completed | Aristotle University Of Thessaloniki | 25 | 2020-03-24 | 2022-04-04 |
| Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification Atropine sulfate and epinephrine, Topical cyclopentolate and phenylephrine - Cataract, Mydriasis | Phase 4 | Unknown | Dar El Oyoun Hospital | 40 | 2018-09-28 | 2018-10-09 |
| Exploration of Pupil Dilation in Horner's Patients Taking Flomax 10% phenylephrine - Horner Syndrome | Phase 4 | Terminated | Denver Health and Hospital Authority | 1 | 2018-09-21 | 2022-03-03 |
| The Effects of α-adrenergic Receptor Antagonists on Choroid and Pupil Alfuzosin Hydrochloride 10 MG, Tamsulosin Hydrochloride 0.4 MG - Benign Prostatic Hyperplasia, Pupil Anomaly | Phase 4 | Completed | Kocatepe University | 63 | 2015-10-29 | 2017-05-09 |
| Interest of a Tetanus Test at a Fixed Remifentanil Concentration Before Laryngoscopy and Skin Incision Remifentanil adapted to SPI, Remifentanil fixed - Intravenous Anesthetic Agent Overdose | Phase 4 | Completed | Erasme University Hospital | 48 | 2013-01-01 | 2017-08-22 |
| Effect of Anti-inflammatory Topical Prednisolone, Nepafenac and Ketorolac in Intra-operative Mydriasis in Facetectomies prednisolone acetate 1%, ketorolac tromethamine 0.4%, nepafenac 0.1% - Cataract | Phase 4 | Unknown | Clinica Oftamologica Zona Sul | 30 | 2009-03-01 | 2011-05-24 |
| Comparison of Instillation and Packing in Mydriasis for Premature Infants 1% tropicamide and 2.5% phenylephrine - Preterm Infants | Phase 4 | Completed | Khon Kaen University | 25 | 2009-03-01 | 2012-03-09 |
| 2.5% and 10% Phenylephrine for Mydriasis in Diabetic Patients With Darkly Pigmented Irides 2.5% or 10% phenylephrine - Diabetes Mellitus | Phase 4 | Completed | Khon Kaen University | 100 | 2007-05-01 | 2012-03-09 |
Mydriasis (9) · Cataract (2) · Retinopathy of Prematurity (2) · Anisocoria (1) · Choroid Diseases (1) · Diabetes Mellitus (1) · Dilatation, Pathologic (1) · Drug-Related Side Effects and Adverse Reactions (1) · Horner Syndrome (1) · Prostatic Hyperplasia (1)
Eye Diseases (13) · Nervous System Diseases (4) · Neurologic Manifestations (4) · Pathological Conditions, Signs and Symptoms (4) · Signs and Symptoms (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Infant, Newborn, Diseases (2) · Infant, Premature, Diseases (2) · Lens Diseases (2) · Retinal Diseases (2) · Autonomic Nervous System Diseases (1) · Brain Diseases (1) · Cavernous Sinus Syndromes (1) · Central Nervous System Diseases (1)
Phenylephrine (5) · Tropicamide (4) · Atropine (1) · Cyclopentolate (1) · Epinephrine (1) · Pilocarpine (1) · Tamsulosin (1) · alfuzosin (1) · proxymetacaine (1)
Aristotle University Of Thessaloniki (2) · Eyenovia Inc. (2) · Khon Kaen University (2) · Clinica Oftamologica Zona Sul (1) · Dar El Oyoun Hospital (1) · Denver Health and Hospital Authority (1) · Erasme University Hospital (1) · Kocatepe University (1) · Prisma Health-Upstate (1) · University of California, San Francisco (1)
United States (4) · Greece (2) · Thailand (2) · Brazil (1) · Egypt (1) · Mexico (1)
Yosanan Yospaiboon, M.D. (2) · Alexandre P Costa, Pinto (1) · Cristos Ifantides, MD (1) · Greg Bennett, MS (1) · Julius Oatts, MD (1) · Mustafa Dogan, Asst. Prof. (1) · Tsontcho Ianchulev, MD, MPH (1)
PMID 20462091, PMID 22368443, PMID 29189318, PMID 34654903, PMID 35428316, PMID 37158245, PMID 39724200, PMID 41338301